NO305275B1 - FremgangsmÕte ved fremstilling av modifisert gruppe B polysakkarid fra Neisseria meningitidis eller modifisert E.coli K1 kapsulµrt polysakkarid - Google Patents

FremgangsmÕte ved fremstilling av modifisert gruppe B polysakkarid fra Neisseria meningitidis eller modifisert E.coli K1 kapsulµrt polysakkarid Download PDF

Info

Publication number
NO305275B1
NO305275B1 NO922316A NO922316A NO305275B1 NO 305275 B1 NO305275 B1 NO 305275B1 NO 922316 A NO922316 A NO 922316A NO 922316 A NO922316 A NO 922316A NO 305275 B1 NO305275 B1 NO 305275B1
Authority
NO
Norway
Prior art keywords
polysaccharide
protein
modified
gbmp
butanoyl
Prior art date
Application number
NO922316A
Other languages
English (en)
Norwegian (no)
Other versions
NO922316D0 (no
NO922316L (no
Inventor
Harold J Jennings
Francis Michon
Original Assignee
Ca Nat Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ca Nat Research Council filed Critical Ca Nat Research Council
Publication of NO922316D0 publication Critical patent/NO922316D0/no
Publication of NO922316L publication Critical patent/NO922316L/no
Publication of NO305275B1 publication Critical patent/NO305275B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
NO922316A 1989-12-14 1992-06-12 FremgangsmÕte ved fremstilling av modifisert gruppe B polysakkarid fra Neisseria meningitidis eller modifisert E.coli K1 kapsulµrt polysakkarid NO305275B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44819589A 1989-12-14 1989-12-14
PCT/CA1990/000437 WO1991008772A1 (en) 1989-12-14 1990-12-13 Improved meningococcal polysaccharide conjugate vaccine

Publications (3)

Publication Number Publication Date
NO922316D0 NO922316D0 (no) 1992-06-12
NO922316L NO922316L (no) 1992-08-14
NO305275B1 true NO305275B1 (no) 1999-05-03

Family

ID=23779371

Family Applications (2)

Application Number Title Priority Date Filing Date
NO922316A NO305275B1 (no) 1989-12-14 1992-06-12 FremgangsmÕte ved fremstilling av modifisert gruppe B polysakkarid fra Neisseria meningitidis eller modifisert E.coli K1 kapsulµrt polysakkarid
NO973311A NO307835B1 (no) 1989-12-14 1997-07-17 Ikke-farmasøytisk polysakkaridkonjugat

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO973311A NO307835B1 (no) 1989-12-14 1997-07-17 Ikke-farmasøytisk polysakkaridkonjugat

Country Status (30)

Country Link
US (3) US5576002A (en:Method)
EP (1) EP0504202B1 (en:Method)
JP (1) JP2637845B2 (en:Method)
KR (1) KR0158436B1 (en:Method)
CN (4) CN1049223C (en:Method)
AR (1) AR243934A1 (en:Method)
AT (1) ATE121947T1 (en:Method)
AU (1) AU641715B2 (en:Method)
BR (1) BR9007917A (en:Method)
CA (1) CA2071811C (en:Method)
CZ (1) CZ283530B6 (en:Method)
DE (1) DE69019164T2 (en:Method)
DK (1) DK0504202T3 (en:Method)
ES (1) ES2071288T3 (en:Method)
FI (2) FI104539B (en:Method)
HR (1) HRP920872A2 (en:Method)
HU (2) HU218146B (en:Method)
IE (1) IE68414B1 (en:Method)
IL (1) IL96676A (en:Method)
IN (1) IN171747B (en:Method)
NO (2) NO305275B1 (en:Method)
NZ (1) NZ236471A (en:Method)
PH (1) PH30305A (en:Method)
PL (2) PL166659B1 (en:Method)
RO (1) RO111416B1 (en:Method)
RU (1) RU2105568C1 (en:Method)
SI (1) SI20008B (en:Method)
WO (1) WO1991008772A1 (en:Method)
YU (1) YU24391A (en:Method)
ZA (1) ZA9010065B (en:Method)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648241A (en) 1989-09-15 1997-07-15 The General Hospital Corporation Conjugate vaccine against group B streptococcus
WO1991008772A1 (en) * 1989-12-14 1991-06-27 National Research Council Of Canada Improved meningococcal polysaccharide conjugate vaccine
ATE203167T1 (de) * 1992-09-24 2001-08-15 Brigham & Womens Hospital Gruppe b streptococcus typ ii und typ v polysaccharid-protein konjugate als impfstoffe
US6153406A (en) * 1993-07-23 2000-11-28 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane protein P2 from Haemophilus influenzae type B
US5439808A (en) * 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US5679654A (en) * 1994-09-02 1997-10-21 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US5700787A (en) * 1994-09-02 1997-12-23 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US5747287A (en) * 1995-04-28 1998-05-05 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US6284884B1 (en) 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
US5811102A (en) * 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
NZ311000A (en) * 1995-06-07 1999-04-29 Smithkline Beecham Biolog Vaccine comprising a polysaccharide antigen-carrier protein conjugate and a free carrier protein
ZA97248B (en) * 1996-01-18 1997-07-18 Rohm & Haas Method for identifying and quantifying polymers utilizing immunoassay techniques
ATE208629T1 (de) 1996-08-27 2001-11-15 Chiron Corp Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung
CA2264585C (en) 1996-08-27 2005-06-14 Chiron Corporation Monoclonal antibodies that define unique meningococcal b epitopes and their use in the preparation of vaccine compositions
US6426074B1 (en) * 1997-03-19 2002-07-30 The Brigham And Women's Hospital Inc. Group B Streptococcus vaccine
JP2002506448A (ja) 1997-06-24 2002-02-26 カイロン コーポレイション 抗髄膜炎菌ワクチン組成物を使用して成体を免疫する方法
PT1007546E (pt) * 1997-08-27 2009-04-24 Childrens Hosp & Res Ct Oak Compostos miméticos moleculares de epítopos de meningococos do serogrupo b
US6248570B1 (en) 1997-12-23 2001-06-19 Baxter International, Inc. Procedures for the extraction and isolation of bacterial capsular polysaccharides for use as vaccines or linked to proteins as conjugate vaccines
PL346645A1 (en) * 1998-08-19 2002-02-25 North American Vaccine IMMUNOGENIC β-PROPIONAMIDO-LINKED POLYSACCHARIDE PROTEIN CONJUGATE USEFUL AS A VACCINE PRODUCED USING AN N-ACRYLOYLATED POLYSACCHARIDE
HK1041825B (zh) * 1998-08-19 2007-02-23 Baxter Healthcare S.A. 多糖-蛋白质缀合物或寡糖-蛋白质缀合物、其制备方法及其应用
US6436653B1 (en) 1998-12-15 2002-08-20 Exiqon A/S Method for introduction of reporter groups into bacterial lipopolysaccharide-derived carbohydrates and the subsequent coupling of such derivatives onto solid surfaces
US7083777B1 (en) * 1999-04-02 2006-08-01 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
US6518037B2 (en) * 1999-11-12 2003-02-11 University Of Iowa Research Foundation Two-component system that controls bacterial membrane synthesis
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
GB0011108D0 (en) * 2000-05-08 2000-06-28 Microscience Ltd Virulence gene and protein and their use
SV2003000753A (es) 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
WO2002083711A2 (en) * 2001-04-17 2002-10-24 Chiron Corporation Molecular mimetics of meningococcal b epitopes which elicit functionally active antibodies
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0121591D0 (en) * 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
EP1490409B1 (en) * 2002-03-26 2008-12-31 Novartis Vaccines and Diagnostics S.r.l. Modified saccharides having improved stability in water
US20060147466A1 (en) * 2002-05-14 2006-07-06 Chiron Srl Mucosal combination vaccines for bacterial meningitis
RU2317106C2 (ru) * 2002-08-02 2008-02-20 ГлаксоСмитКлайн Байолоджикалз с.а. Нейссериальные вакцинные композиции, содержащие комбинацию антигенов
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
WO2004089407A2 (en) 2003-03-31 2004-10-21 The Brigham And Women's Hospital, Inc. Zwitterionic immunomodulators for the treatment of asthma and allergy
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
KR101113726B1 (ko) 2003-08-12 2012-02-27 리폭센 테크놀로지즈 리미티드 단백질 유도 및 컨쥬게이션용 시알산 유도체
US8148335B2 (en) 2004-06-23 2012-04-03 Children's Hospital & Research Center Oakland De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
CA2568982A1 (en) * 2004-06-23 2006-01-05 Children's Hospital & Research Center At Oakland Polysaccharide derivatives and uses in induction of an immune response
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
PL1896061T3 (pl) 2005-06-27 2020-02-28 Glaxosmithkline Biologicals S.A. Kompozycja immunogenna
US8206726B2 (en) 2006-02-06 2012-06-26 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
GB0611914D0 (en) 2006-06-15 2006-07-26 Teti Giuseppe Peptides that mimic non-human cross-reactive protective epitopes of the group Bmeningococcal capsulsar polysaccharide
EP1872791A1 (en) * 2006-06-30 2008-01-02 Institut Pasteur Use of bacterial polysaccharides for biofilm inhibition
WO2008157590A1 (en) * 2007-06-20 2008-12-24 Baxter International Inc. Modified polysaccharides for conjugate vaccines
WO2009076158A1 (en) 2007-12-07 2009-06-18 Novartis Ag Compositions for inducing immune responses
EP2387417B1 (en) 2009-01-16 2016-05-11 University of Maryland, Baltimore Broad spectrum vaccine against non-typhoidal salmonella
EP2731617A4 (en) 2011-07-12 2015-07-01 Brigham & Womens Hospital LIPID-BASED PSA COMPOSITIONS, METHOD FOR THEIR INSULATION AND USE METHOD THEREFOR
EP2752403A1 (de) * 2013-01-08 2014-07-09 Sika Technology AG Amin für emissionsarme Epoxidharz-Produkte
WO2017031431A1 (en) 2015-08-19 2017-02-23 President And Fellows Of Harvard College Lipidated psa compositions and methods
EP3484441A4 (en) 2016-07-15 2020-03-18 President and Fellows of Harvard College GLYCOLIPID COMPOSITIONS AND METHOD FOR USE
CN110234658B (zh) * 2017-01-31 2024-03-12 辉瑞大药厂 脑膜炎奈瑟菌组合物及其使用方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) * 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4619828A (en) * 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
US4644059A (en) * 1982-07-06 1987-02-17 Connaught Laboratories, Inc. Haemophilus influenzae B polysaccharide-diptheria toxoid conjugate vaccine
US4496538A (en) * 1982-07-06 1985-01-29 Connaught Laboratories, Inc. Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
WO1991008772A1 (en) * 1989-12-14 1991-06-27 National Research Council Of Canada Improved meningococcal polysaccharide conjugate vaccine

Also Published As

Publication number Publication date
NZ236471A (en) 1992-10-28
US5902586A (en) 1999-05-11
PL288271A1 (en) 1991-12-16
HU9201966D0 (en) 1992-10-28
WO1991008772A1 (en) 1991-06-27
EP0504202B1 (en) 1995-05-03
HRP920872A2 (en) 1997-06-30
HU218146B (hu) 2000-06-28
FI19991917A7 (fi) 1999-09-09
BR9007917A (pt) 1992-10-20
HUT64480A (en) 1994-01-28
JP2637845B2 (ja) 1997-08-06
NO973311L (no) 1992-08-14
IL96676A0 (en) 1991-09-16
CZ628490A3 (en) 1997-12-17
US5576002A (en) 1996-11-19
CN1072506C (zh) 2001-10-10
CN1036522C (zh) 1997-11-26
CA2071811C (en) 2003-11-04
ATE121947T1 (de) 1995-05-15
DE69019164D1 (de) 1995-06-08
NO922316D0 (no) 1992-06-12
IL96676A (en) 1996-09-12
CN1100656A (zh) 1995-03-29
CZ283530B6 (cs) 1998-04-15
YU24391A (sh) 1995-12-04
KR0158436B1 (ko) 1998-12-01
PL166035B1 (pl) 1995-03-31
DE69019164T2 (de) 1995-09-07
IN171747B (en:Method) 1992-12-26
ES2071288T3 (es) 1995-06-16
FI922737A0 (fi) 1992-06-12
FI19991917L (fi) 1999-09-09
IE904513A1 (en) 1991-06-19
PH30305A (en) 1997-02-20
FI104539B (fi) 2000-02-29
AR243934A1 (es) 1993-09-30
NO973311D0 (no) 1997-07-17
SI20008B (en) 2001-02-28
AU6898791A (en) 1991-07-18
AU641715B2 (en) 1993-09-30
NO922316L (no) 1992-08-14
SI20008A (sl) 2000-02-29
CN1100428A (zh) 1995-03-22
US5683699A (en) 1997-11-04
ZA9010065B (en) 1992-02-26
DK0504202T3 (da) 1995-10-02
EP0504202A1 (en) 1992-09-23
JPH05505392A (ja) 1993-08-12
RO111416B1 (ro) 1996-10-31
CN1036504C (zh) 1997-11-26
NO307835B1 (no) 2000-06-05
RU2105568C1 (ru) 1998-02-27
PL166659B1 (pl) 1995-06-30
CA2071811A1 (en) 1991-06-15
CN1055541A (zh) 1991-10-23
CN1049223C (zh) 2000-02-09
CN1096516A (zh) 1994-12-21
IE68414B1 (en) 1996-06-12

Similar Documents

Publication Publication Date Title
NO305275B1 (no) FremgangsmÕte ved fremstilling av modifisert gruppe B polysakkarid fra Neisseria meningitidis eller modifisert E.coli K1 kapsulµrt polysakkarid
JP4171068B2 (ja) 修飾したメニンゴコッカスのポリサッカライドを結合したワクチン
JPH06503465A (ja) 髄膜炎菌のクラスｉの外膜タンパク質のワクチン
US7595307B2 (en) Polysaccharide derivatives and uses in induction of an immune response